Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 18;52(1):613.
doi: 10.1007/s11033-025-10638-5.

Circular RNA rising star: new findings of circPRMT5 in cancer

DuanZhong Chen  1   2 , CaiYan Yin  1   2 , Chao Li  1 , Jun He  3 , Peng Wu  4   5
Affiliations
Review

Circular RNA rising star: new findings of circPRMT5 in cancer

DuanZhong Chen et al. Mol Biol Rep. .

Abstract

Circular RNA (circRNA), a type of noncoding RNA, features a covalently closed circular structure lacking 5'-3' polarity and a polyadenylated tail. Its resistance to RNase R degradation endows it with greater stability and resilience than linear RNA, leading to a prolonged half-life. Recent research has highlighted the crucial role of circRNAs, especially circPRMT5, in diverse cancers. CircPRMT5 is generated by reverse splicing of exon 18 within a 682-nucleotide gene. In various cancer cells, elevated circPRMT5 expression is correlated with increased tumor cell proliferation, migration, and invasion abilities. It impacts tumor progression by regulating cell proliferation, migration, invasion, and chemotherapy resistance. This review comprehensively examines the expression patterns, mechanisms, and clinical potential of circPRMT5 in cancers such as breast, bladder, nonsmall cell lung, esophageal, thyroid, liver, colorectal, and gastric cancer. Overall, circPRMT5 shows promise as a biomarker and therapeutic target, providing valuable insights for future cancer research and treatment strategies.

Keywords: Cancer; CircPRMT5; Circular RNA; Drug resistance; Mechanisms; Therapy.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval: This article does not contain any studies with human participants or animals performed by any of the authors.

References

    1. Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660 - DOI - PubMed
    1. Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492 - DOI - PubMed
    1. Bray F, Soerjomataram I (2015) The Changing Global Burden of Cancer: Transitions in Human Development and Implications for Cancer Prevention and Control. In: Gelband H, Jha P, Sankaranarayanan R, Horton S (eds) Cancer: Disease Control Priorities, Third Edition (Volume 3). The International Bank for Reconstruction and Development / The World Bank, Washington (DC)
    1. Xie J, Ye F, Deng X et al (2023) Circular RNA: a promising new star of vaccine. J Transl Intern Med. https://doi.org/10.2478/jtim-2023-0122 - DOI
    1. Zheng X, Song L, Cao C, Sun S (2025) Multiple roles of circular RNAs in prostate cancer: from the biological basis to potential clinical applications. Eur J Med Res. https://doi.org/10.1186/s40001-025-02382-0 - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources